Pediatrix Medical Group (NYSE:MD) Upgraded at Jefferies Financial Group

Pediatrix Medical Group (NYSE:MD) was upgraded by equities researchers at Jefferies Financial Group from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Marketbeat.com reports. The firm presently has a $14.00 target price on the stock, up from their prior target price of $8.00. Jefferies Financial Group’s price objective would indicate a potential upside of 24.33% from the stock’s previous close.

Several other research analysts also recently weighed in on MD. StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Truist Financial increased their price target on Pediatrix Medical Group from $8.00 to $10.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. UBS Group increased their price target on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating and set a $8.00 price target for the company in a research note on Friday, June 7th. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $10.30.

Pediatrix Medical Group Stock Down 0.9 %

Shares of NYSE:MD opened at $11.26 on Thursday. The company has a market capitalization of $947.50 million, a PE ratio of -13.25, a price-to-earnings-growth ratio of 1.64 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. The business has a fifty day moving average price of $10.04 and a two-hundred day moving average price of $8.88. Pediatrix Medical Group has a 1 year low of $6.62 and a 1 year high of $13.01.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.03. The firm had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The business’s revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.37 EPS. Analysts forecast that Pediatrix Medical Group will post 1.18 earnings per share for the current year.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Pediatrix Medical Group news, Director Laura A. Linynsky sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now owns 30,805 shares of the company’s stock, valued at approximately $343,783.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO James D. Swift sold 11,100 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $10.79, for a total value of $119,769.00. Following the completion of the sale, the chief executive officer now directly owns 170,001 shares in the company, valued at approximately $1,834,310.79. The disclosure for this sale can be found here. Insiders have sold a total of 68,100 shares of company stock valued at $701,889 in the last 90 days. Corporate insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Clark Estates Inc. NY bought a new position in Pediatrix Medical Group during the 4th quarter worth approximately $3,302,000. Aristeia Capital L.L.C. bought a new position in Pediatrix Medical Group during the 2nd quarter worth approximately $687,000. Boston Partners grew its position in shares of Pediatrix Medical Group by 34.0% in the 1st quarter. Boston Partners now owns 1,786,434 shares of the company’s stock worth $17,702,000 after buying an additional 453,254 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Pediatrix Medical Group by 1.6% in the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after buying an additional 164,333 shares during the last quarter. Finally, Rubric Capital Management LP grew its position in shares of Pediatrix Medical Group by 797.0% in the 2nd quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock worth $61,532,000 after buying an additional 7,241,400 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.